DeutschNewstral
Article
Mmarketwatch.com on 2017-06-27 15:08
Innate Immunotherapeutics stock plummets 92% after midstage clinical trial miss
Related news
- MUPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial missmarketwatch.com
Brutal losses as stock market plummets againnews.com.au
Incyte stock plummets following disappointing clinical study resultsbizjournals.com- PInogen stock plummets after reporting earnings misspacbiztimes.com
- MPhibro stock plummets on earnings miss, outlookmarketwatch.com
- MPure Storage stock plummets more than 15% after earnings missmarketwatch.com
- MChildren's Place stock plummets 17% after sales miss, guidance cutmarketwatch.com
- MKirkland's stock plummets 20% after earnings, sales and SSS missmarketwatch.com
- MPerformance Food's stock plummets after earnings miss, downbeat outlookmarketwatch.com
- MTwitter stock plummets after earnings miss trumps user-growth beatmarketwatch.com
- MEventbrite stock plummets 20% after earnings miss, revenue beatmarketwatch.com
- MSymantec stock plummets as CEO steps down amid earnings missmarketwatch.com
- MGoPro stock plummets 15% following big earnings, sales missmarketwatch.com
- MStamps.com stock plummets nearly 40% after revenue miss, revised guidancemarketwatch.com
- Juno stock plummets, FDA timeline up in air after clinical trial suspensionbizjournals.com
Dr. Price’s marvelous medicine for your stock portfolioWashington Post
Contrary To Sworn Testimony, Company Confirms Trump's HHS Pick Got Special Stock Dealhuffingtonpost.com- MOncoMed Pharma stock drops 17% after clinical trial miss; Q1 revenue missmarketwatch.com
Report: Fired U.S. Attorney Bharara was investigating Tom Price’s stock trades - Fri, 17 Mar 2017 PSTThe Spokesman-Review- MFerroglobe's stock plummets toward record low as deteriorating conditions lead to earnings, sales missmarketwatch.com